Understand the reasoning behind the recommendation.

Search appraisal precedent across HTA bodies and examine how each assessed the population, comparator, clinical benefit and economic case.

Read recommendations in their published context. Compare model methods, conditions of use and key uncertainties to inform your evidence strategy and payer discussions.

Compare the reasoning, not just the recommendation

Find relevant appraisals and examine the assessed population, accepted comparators and clinical endpoints. Read each recommendation with its conditions rather than treating the headline decision as a medicine-wide conclusion.

Examine the economic case

Review recorded model methods, incremental cost-effectiveness ratios (ICERs), quality-adjusted life years (QALYs) and uncertainty where they were published. Confidential prices and unpublished commercial terms are not shown.

Worked example: NICE TA393

The alirocumab appraisal brings the published recommendation together with 14 verified trial endpoint results and the recorded economic methods: a Markov model with a one-year cycle and a 3.5% discount rate. These details describe this appraisal, not a template for other decisions.

Build a focused payer discussion

Use precedent to identify questions about your population, comparator and evidence package. Decisions from different bodies stay labelled by agency and jurisdiction; one body's recommendation does not establish another's position.

Request an HTA Library demonstration